Meta Pixel

News and Announcements

Dovetail’s Offerings reach 50% subscription, Dovetail’s Townhouse Project 2 Floors Built & New Offer Launches with 6 month Duration

  • Published March 12, 2020 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Whilst stock markets crash and industries stall, Dovetail continues to power through 2020 with a clear vision of delivering their five townhouse & childcare projects in Melbourne’s Bayside.

They had strong reception recently showcasing their projects at Wholesale Investor’s Emergence 2020 Conference in Sydney. Since returning to Melbourne, having met over 100 investors and 40 expressing interest, all projects have begun securing investment, with two project seeing 50% of the subscription filled!


In case you missed Founding Director, Cameron Bloomfield, pitch Dovetail and their 3 current offerings, head over to Dovetail’s deal rooms on CRIISP to watch the recording.

In less than two months, Dovetail’s Townhouse project has completed both slab and frame stage (photo shown). With the swift start to the build program, this project is on track for completion in 10 months, and you can still be part of this exciting venture with double digit investment opportunities available for a limited time.

Dovetail has launched a second townhouse project on the CRIISP platform, this time with a 6 month investment time-frame, yet still offering investors returns between 16-26% p.a. Search ‘Dovetail’ within CRIISP to view the offering.

For any further information contact Cameron on 03 9583 3486 or [email protected]

 

About Dovetail Developments

Dovetail Developments is a multi-awarded property development company located in Melbourne’s South East specialising in developing architecturally inspired multi-unit townhouse projects and childcare centres. Dovetail provides a holistic end-to-end service offering, encompassing property research, acquisition, design, sales & marketing, finance and project management.

Register Interest

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now